PHARMACEUTICAL STOCKS
Stock Picks of the Week: 5 stocks with consistent score improvement and upside potential of up to 35% in 1 year, according to analysts
The market weathered a whole bad patch with almost no FPI money coming in. But it cuts the other way too. When so little has been flowing in, even a small amount of FPI buying can move the market more than it normally would. That said, the mood has turned from bearish to cautiously optimistic, thanks largely to dropping oil prices. None of that changes your basic job as an investor: Study companies, look at earnings, and keep quality front and centre.
Gland Pharma shares jump 4% after Q2 profit jumps 58%, revenue rises 23% YoY
Gland Pharma shares rose 3.89% after reporting strong Q2 FY27 results, with revenue growing 23% and net profit jumping 58% year-on-year. The stock touched a 52-week high of Rs 3,345, supported by robust CDMO growth, improved margins, new product launches and increased US regulatory approvals.
AMFI reshuffle: Jio Platforms and NSE may get largecap status, Vedanta may become midcap in H1 CY27
Nuvama expects Jio Platforms and NSE to enter AMFI's largecap category in its H1 CY27 reshuffle, while Vedanta may move to midcap status. The proposed changes also include upgrades and downgrades across midcap and smallcap stocks, with revised market-cap thresholds estimated at Rs 1.12 lakh crore and Rs 36,700 crore.
Sai Life Sciences shares jump 9%, multibagger stock rallies 19% in 3 days after Q2 results. Why Jefferies hiked target price
Sai Life Sciences shares hit a fresh 52-week high on Monday after strong Q2 results and bullish brokerage commentary. Jefferies retained its Buy rating and raised its target price to Rs 2,050, citing healthy CRO and CDMO growth, a strengthening pipeline and improved earnings prospects.
Divi’s Laboratories shares gain another 5% after Q2 results. Here’s why Jefferies raised target price by 23%
Shares of Divi’s Laboratories jumped 5% following a 64% YoY surge in Q2 FY27 net profit to Rs 1,127 crore. Brokerage Jefferies raised its target price by 23% to Rs 12,550, citing robust CDMO business expansion, strong EBITDA margins, and a solid GLP peptide pipeline.
South Korean shares rebound as chipmakers recover from AI-driven selloff
South Korean shares rebounded on Monday as benchmark index KOSPI rose over 1.5%. Chip giants Samsung Electronics and SK Hynix led the recovery following Wall Street gains and government assurances over Nvidia GPU supply continuity, despite remaining net selling pressure from foreign investors.
- Go To Page 1
Will Nifty's winning streak light up Muhurat trading? Check strategy and stock picks for festive gains
Muhurat Trading Stock picks 2026: Indian equities are experiencing a significant rally ahead of the Diwali Muhurat trading session on November 8. Analysts are highlighting opportunities in sectors such as banking, automobiles, pharmaceuticals, and largecap stocks. The recent surge in the Nifty marks a substantial recovery after a challenging financial year. Investors are advised to adopt a long-term investment strategy during the ceremonial trading session.
PSBs, pharma and defence: HDFC Securities CEO names Samvat 2083’s dark horses
HDFC Securities MD and CEO Dhiraj Relli identifies public sector banks, pharmaceuticals and defence as potential outperformers in Samvat 2083. He favours largecaps for valuation comfort, highlights selective stock opportunities and urges investors to prioritise earnings visibility and disciplined asset allocation.
Muhurat Trading 2026: Which stocks to buy during special session today? Analysts list top technical picks
Investors are preparing for the Muhurat Trading session today, which marks the beginning of Samvat 2083. Stock exchanges BSE and NSE will hold the session for an hour starting at 2.20 pm. Analysts from HDFC Securities and Axis Securities have identified several stocks as top picks for this trading period. Stocks like HCL Technologies and IIFL Finance have been highlighted for their potential upside.
For long- and medium-term investors: Cycles turn, principles don’t; 5 large-cap stocks with upside potential of up to 29%
These are the stocks that fell the most, so they may bounce back the most if the fund flows return. They are the ones FPI money will target first. And they tend to be the businesses with great track records, the ones that have been through bad patches like this before and have come out unscathed. Yes, we are talking about large-cap stocks.
Divi's Labs Q2 Results: PAT surges 64% YoY to Rs 1,127 crore; revenue jumps 35%
Divi's Laboratories has achieved a remarkable profit surge of 63.6% year-on-year for the September quarter of FY27, driven by a 35.4% increase in operational revenue, totaling Rs 3,676 crore. The company's total income reached Rs 3,770 crore in Q2FY27, while the first half of the fiscal year saw total earnings hit Rs 6,907 crore.
Diwali 2026 wealth creators: 8 BSE 500 stocks shrug off market weakness, deliver up to 191% returns; do you own any?
Eight BSE 500 stocks more than doubled investors’ wealth since Diwali 2025, led by Aditya Infotech, HFCL and Welspun Corp. As Samvat 2083 begins, brokerages expect earnings-led growth, favouring selective investments across banking, manufacturing, consumption, exports and technology amid valuation concerns.
These large-, mid- and small-cap stocks have upside potential of up to 31% in 1 year, according to analysts
In the last two years, the world has learnt that you can never quite predict what US President Trump will do next. Tomorrow, to pull attention one way or another, there could well be some more action against Iran, changing the mood again in a single afternoon. So, the improvement in sentiment is real, but it is also fragile.
Sai Life Sciences shares rally 9% after Q2 results; net profit rises 17%, revenue up 23%
Sai Life Sciences shares jumped nearly 9% to a fresh 52-week high after strong second-quarter results. Revenue rose 23%, while net profit increased 17%, supported by sustained business momentum and growing engagement with global pharmaceutical companies.
Stocks in news: Bharti Airtel, LIC, Titan, ONGC, Bharti Hexacom, Glenmark Pharma and Astral
Indian equity markets continued their upward trend, highlighted by the Nifty 50 gaining 576 points. Bharti Airtel, LIC, and Titan Company reported strong profit increases for the September quarter. ONGC also posted a substantial rise in consolidated profit compared to last year. In contrast, Glenmark Pharmaceuticals faced a significant decline in net profit this quarter. Overall, corporate developments are influencing investor sentiment as markets react to earnings reports.
Glenmark Pharma Q2 Results: Net profit plunges 56% to Rs 264 crore, revenue down at Rs 4,247 cr
Glenmark Pharmaceuticals experienced a 56.78 percent drop in consolidated profit after tax during the September quarter. Total revenue from operations decreased to Rs 4,247.32 crore compared to the previous year. The company's total expenses also decreased during the same period, indicating some operational efficiency. A subsidiary of Glenmark Pharma entered into a settlement for USD 15 million with Humana Inc.
AI selloff drags Nikkei lower despite broad-based market gains
Japan's Nikkei 225 fell 0.5% on Thursday as losses in AI and semiconductor stocks offset gains across the broader market. Concerns over a potential slowdown in data centre investments weighed on chipmakers, even as falling crude oil prices lifted the Topix 1.3%, with real estate, retail and pharmaceutical stocks leading gains.
Pills are paying off! Pharma stocks lead 2026 rally with up to 112% return
In 2026, India's pharmaceutical stocks are making headlines with impressive year-to-date gains. This surge is driven by strong domestic demand alongside enhanced profitability from new product launches. Notable players like Laurus Labs and Gland Pharma have recorded remarkable returns, topping 100%. Amid challenges faced by other sectors, the pharmaceutical field demonstrates resilience. Analysts are optimistic but advise exercising caution regarding potential market volatility and the durability of this sector's performance.
These mid-caps have ‘strong buy’ & ‘buy’ recos and upside potential of up to 28%, according to analysts
Global markets on Wednesday celebrated the outcome of the US mid-term election as well as a sharp drop in oil prices. Oil prices, which at the end of last week were at about $118 to the barrel, are now under $95. The hope clearly is that Democrat control of both chambers of the US Congress will pressure the Trump administration to pursue a diplomatic end to the conflict with Iran in the Gulf.
Emcure Pharma shares hit 10% upper circuit after FY27 guidance hike; Jefferies raises target price by 8%
Emcure Pharma shares hit a 10% upper circuit after strong Q2 FY27 results prompted the company to raise its full-year growth guidance. Brokerages turned more positive, citing robust international business, improving domestic growth and a strong product pipeline.
European shares fall as tech stocks slide, Middle East tensions weigh
European shares declined as technology stocks led losses amid concerns over AI valuations and escalating US-Iran tensions. Rising oil prices added pressure, while stronger earnings expectations lifted healthcare stocks, with Bayer gaining 6% after raising its 2026 profit outlook.
Bayer raises 2026 profit outlook on strong pharmaceuticals performance
Bayer raised its 2026 profit outlook after its pharmaceuticals division delivered stronger-than-expected third-quarter sales. The German group also lowered its debt forecast, signalling improving growth momentum and a stronger financial position.
Hunting for Diwali winners? 8 brokerages name 58 stocks with big upside potential; Eternal, L&T among top picks
Eight brokerages have shortlisted 58 stocks for their Diwali 2026 portfolios across sectors such as banking, IT, defence, automobiles and hospitality. Eternal, L&T and Indian Hotels are the most popular picks, featuring in four brokerage portfolios each, while Kotak Mahindra Bank appears in three. ICICI Bank, Tech Mahindra, Tata Steel and Adani Ports are among the other recurring recommendations.
Jubilant Pharmova plans to raise Rs 800 crore via maiden bond issue
Jubilant Pharmova has announced plans to secure ₹800 crore via its first bond issuance within the local market, featuring ₹400 crore as the base amount and an equal greenshoe option. The capital raised will be primarily allocated to the company’s capital expenditure and upcoming expansion efforts. Subscriptions are anticipated chiefly from mutual funds and asset managers, making this a significant moment in the company's bond market debut.
Stocks in news: ITC, Marico, SBI, Yatra Online, NSE, Container Corp and Sun Pharma
Indian equity benchmarks experienced gains, with Nifty nearing the 23,500 resistance level and strong corporate earnings reported. ITC faced a decline in consolidated net profit, impacted by the cigarette business, despite revenue growth. Marico saw a significant rise in net profit and expanding EBITDA margins during the quarter. Container Corporation of India reported a subdued performance with a slight decline in net profit compared to last year.
Mold-Tek Packaging shares surge 17% as Q2 FY 27 profit jumps 35% YoY to Rs 21 crore
Mold-Tek Packaging shares surged nearly 17% after the company reported a 35.5% YoY rise in Q2 FY27 net profit and 30.5% revenue growth. Strong pharma and FMCG packaging volumes supported performance, while new product launches and expansion plans strengthened its growth outlook.
Diwali 2026: 77 stocks knock down D-St bears to deliver multibagger returns of up to 4,700% in a year
With Diwali 2026 on the horizon, 77 stocks have thrived despite market fluctuations, marking exceptional returns. Mrugesh Trading showcases an astonishing gain of 4,657%, while Axis Solution follows closely with 1,081%. Other strong performers are Sterlite Technologies and Cupid, each demonstrating impressive growth. Analysts are hopeful for a market rebound thanks to falling crude oil prices, which could positively impact sectors such as automotive, capital goods, and pharmaceuticals.
Short-term headwinds, yes; owning the ecosystem is better: 20 healthcare stocks with downside risk of 23% to upside potential of 41%
The healthcare sector is under scrutiny. The issue is pricing: What medicines cost and on what hospitals and the rest of the health ecosystem charge. And both the government and the courts have stepped in. At one level, that is not entirely a bad thing. Check out Stock Reports Plus, powered by Refinitiv, for price targets of over 4,000 listed stocks along with detailed company analysis focusing on five key components – earnings, fundamentals, relative valuation, risk, and price momentum – to generate standardised scores. SR+ Reports is a complimentary offering to ETPrime members.
Load More
